← Back to patent-cliff list
RSC-1001
Tier C — Watch / tradeRSC-1001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Hyperlipidaemia, Dyslipidaemia
Regional status
US
-
EU
-
China
Phase II
2026-09-23
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RSC-1001?
Approved indications include: Hyperlipidaemia, Dyslipidaemia.
When does the RSC-1001 patent expire?
No public expiry year is available for RSC-1001 yet; this page updates once verified.
How do I get a quote for RSC-1001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28